10x Genomics (TXG) Cash from Investing Activities (2018 - 2026)

10x Genomics has reported Cash from Investing Activities for 9 years, with the latest figure at -$1.3 million in Q1 2026.

• Quarterly Cash from Investing Activities rose 30.74% year-over-year to -$1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$12.9 million (up 71.53% YoY) and the FY2025 annual result came in at -$13.4 million, up 58.82% from the prior year.
• Cash from Investing Activities advanced to -$1.3 million in Q1 2026 per TXG's latest filing, from -$1.8 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $120.0 million in Q1 2023 and troughed at -$257.6 million in Q1 2022.
• A 5-year average of -$15.6 million and a median of -$1.9 million in 2025 frame the typical range for Cash from Investing Activities.
• The widest YoY moves for Cash from Investing Activities: up 367.75% in 2024, down 493.89% in 2024.
• Over 5 years, Cash from Investing Activities stood at -$33.2 million in 2022, then soared by 139.49% to $13.1 million in 2023, then sank by 493.89% to -$51.6 million in 2024, then surged by 96.5% to -$1.8 million in 2025, then rose by 27.37% to -$1.3 million in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered -$1.3 million, -$1.8 million, and -$8.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.